

University of Groningen

Use of real-world evidence in pharmacoeconomic analysis

Huang, Yunyu

DOI:
[10.33612/diss.95669767](https://doi.org/10.33612/diss.95669767)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Huang, Y. (2019). *Use of real-world evidence in pharmacoeconomic analysis: illustrations in The Netherlands and China*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.95669767>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

PROPOSITIONS

to accompany the PhD thesis

Use of Real-World Evidence in Pharmacoeconomic Analysis

- Illustrations for The Netherlands and China

1. Value for money and efficiency are fundamental considerations guiding investment in health (*World Health Organization*)
2. Health economics and outcomes research (HEOR) is becoming increasingly important as a tool for assessing new pharmaceuticals throughout the world (*this thesis*)
3. Real-world evidence (RWE) can complement randomized controlled trials to examine drugs' effectiveness in larger patient populations in routine clinical settings (*this thesis*)
4. Data quality assessment helps to ensure the validity of RWE and improves the appropriateness of the use of RWE in different settings (*this thesis*)
5. Potential issues related to RWE, including confounding and missing data, can be minimized through appropriate analytical methods to improve the internal validity of real-world studies (*this thesis*)
6. Pharmacoeconomic analyses using local RWE can be highly valuable for healthcare decision makers to develop country-specific cost-effective strategies (*this thesis*)
7. Perfect is the enemy of good (*Voltaire*)
8. Choose what you can speak to speak, choose what you can do to do – 择可言而后言，择可行而后行 (*Kuan tzu*)

Yunyu Huang

02 April 2019